John Patrick Shannon, Jr. Sells 23,242 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider John Patrick Shannon, Jr. sold 23,242 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $7.46, for a total transaction of $173,385.32. Following the completion of the transaction, the insider owned 2,643,153 shares of the company’s stock, valued at approximately $19,717,921.38. The trade was a 0.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $7.08 on Wednesday. The firm has a 50 day simple moving average of $8.33 and a 200 day simple moving average of $6.54. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.86 and a 52 week high of $10.08. The company has a market cap of $1.17 billion, a PE ratio of -70.79 and a beta of 0.21.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter valued at approximately $35,000. Northwestern Mutual Wealth Management Co. lifted its stake in Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after acquiring an additional 5,000 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in Xeris Biopharma in the third quarter worth approximately $68,000. Xponance Inc. acquired a new position in shares of Xeris Biopharma during the 1st quarter worth $57,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Xeris Biopharma during the 3rd quarter valued at $85,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on XERS shares. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Leerink Partners raised their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 19th. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.58.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.